Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.80
Bid: 29.00
Ask: 30.70
Change: -0.90 (-2.93%)
Spread: 1.70 (5.862%)
Open: 28.80
High: 29.80
Low: 28.80
Prev. Close: 30.70
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DiaSpect Tm McKesson US distribution agreement

9 Aug 2018 07:00

RNS Number : 2695X
EKF Diagnostics Holdings PLC
09 August 2018
 

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

DiaSpect Tm US distribution agreement with McKesson

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation - the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue - for the Company's hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.

 

The DiaSpect Tm is the world's fastest hemoglobin analyzer and will be branded in the US by McKesson under its own branded line, as the McKesson Consult® Hb analyzer.

 

The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the DiaSpect Tm in April 2018, approving the product for use in point of care and Certificate of Waiver settings. Sales of the McKesson Consult® Hb analyzer are expected following full launch in the autumn, 2018.

 

For more information on the DiaSpect Tm see: www.ekfdiagnostics.com/diaspect.html 

 

Commenting, Julian Baines, CEO of EKF, said:  

"As I said in April the US market is a key target for the DiaSpect Tm, which gives physicians access to an easy to use, accurate and portable hemoglobin measurement system able to deliver laboratory quality results at the point of care within seconds." 

 

"This agreement with McKesson allows us to offer this innovative technology to physicians and childcare specialists across the US through the market's leading and most established healthcare distribution player. We expect that this partnership will ultimately deliver significant value to shareholders."

 

 

Enquiries:

 

EKF Diagnostics Holdings plc 

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About McKesson Medical-Surgical mms.mckesson.com

McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson Medical-Surgical works with health systems, physician offices, extended care providers, in-home patients, labs, payers and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRDDGDIRBGBGII
Date   Source Headline
25th Aug 20151:10 pmRNSHolding(s) in Company
25th Aug 201511:54 amPRNForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201511:30 amBUSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201510:52 amRNSHolding(s) in Company
24th Aug 201511:19 amRNSForm 8.3 - EKF Diagnostics Holdings Plc
24th Aug 20157:01 amRNSAnnouncement under rule 2.4 of the Takeover Code
24th Aug 20157:00 amRNSFurther non-binding proposal
18th Aug 201512:00 pmRNSConclusion of Strategic Review
18th Aug 201511:55 amRNSTrading update
10th Aug 20159:25 amRNSHolding(s) in Company
19th May 20152:26 pmRNSResult of AGM
13th May 20157:00 amRNSLaunch of PrecisionPath Colon
1st May 20153:15 pmRNSPosting of Annual Report & Notice of AGM
24th Apr 20154:44 pmRNSHolding(s) in Company
21st Apr 20151:17 pmRNSData for PointMan Technology presented at AACR
8th Apr 201511:41 amRNSHolding(s) in Company
8th Apr 201511:36 amRNSHolding(s) in Company
2nd Apr 20157:00 amRNSShareholder update
26th Mar 20153:47 pmRNSHolding(s) in Company
25th Mar 20153:05 pmRNSHolding(s) in Company
19th Mar 20159:40 amRNSHolding(s) in Company
18th Mar 20153:41 pmRNSHolding(s) in Company
16th Mar 20157:00 amRNSFinal Results
2nd Mar 20157:00 amRNSCollaboration to improve colon cancer treatment
23rd Feb 20157:00 amRNSNotice of results & investor results presentation
2nd Feb 20157:00 amRNSChange of Adviser
28th Jan 20157:00 amRNSTrading update
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
5th Jan 20157:00 amRNSPayment of DiaSpect's deferred consideration
17th Dec 20147:00 amRNSTrading update & potential Board appointment
11th Nov 20144:46 pmRNSHolding(s) in Company
1st Oct 201411:36 amRNSDirector/PDMR Shareholding
23rd Sep 20147:00 amRNSUS collaboration to develop blood tests for cancer
15th Sep 20147:00 amRNSHalf Yearly Report
15th Aug 20147:00 amRNSDirectorate Change
13th Aug 20147:00 amRNSNotice of results and investor briefing
23rd Jul 20147:00 amRNSTrading update
8th Jul 20147:00 amRNSContract Win and Regulatory Approval
13th Jun 201412:53 pmRNSHolding(s) in Company
9th Jun 20145:59 pmRNSGrant of Share Options
6th Jun 20142:46 pmRNSHolding(s) in Company
2nd Jun 20144:15 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSMajor step towards detecting cancer in blood
2nd Jun 20147:00 amRNSDirectorate Change
27th May 20143:59 pmRNSHolding(s) in Company
23rd May 201411:30 amRNSHolding(s) in Company
21st May 20144:40 pmRNSSecond Price Monitoring Extn
21st May 20144:35 pmRNSPrice Monitoring Extension
20th May 20144:36 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.